National Health Act 1953 - Declaration under subsection 85(2AA) (No. PB 6 of 1997)

Overview

The National Health Act 1953 was enacted by the Parliament of Australia to provide a legislative framework for the administration of national health schemes and related matters, including the Pharmaceutical Benefits Scheme (PBS). This Act was introduced to address the need for a coordinated and comprehensive approach to providing access to essential medicines and treatments for the Australian population. In 1997, a legislative instrument was issued under the authority of the Act to amend the PBS by removing certain drugs and medicinal preparations from the list of subsidised medications. The policy objective of this amendment was to refine the scope of the PBS to ensure that resources were directed towards treatments that provided the greatest benefit to public health. The instrument, which took effect on 1 May 1997, specified that particular drugs, such as Ethinyloestradiol, would no longer be covered under Part VII of the National Health Act 1953, thereby altering the eligibility criteria for pharmaceutical benefits.

Scope and Application

The National Health Act 1953, as modified by this legislative instrument, applies to the cessation of certain drugs and medicinal preparations from the scope of Part VII of the Act. This particular declaration, made under subsection 85(2AA), concerns the removal of specified drugs from the Pharmaceutical Benefits Scheme (PBS), thereby altering their eligibility for government subsidies. The legislative instrument identifies the cessation of the drug ethinyloestradiol from the PBS as of 1 May 1997. The declaration is geographically applicable across the Commonwealth of Australia and impacts entities and individuals relying on the PBS for subsidised medication. The exclusion of these specified drugs from Part VII of the Act effectively restricts their eligibility for government subsidies under the PBS, impacting patients, healthcare providers, and pharmaceutical entities involved in the supply and reimbursement of these medications. This legislative action does not introduce new exclusions or exemptions but rather modifies the existing framework by removing certain drugs from the list of those covered under the Act.

Key Provisions

The main operative sections of this Declaration under subsection 85 (2AA) of the National Health Act 1953 specify that the drugs and medicinal preparations listed in the Schedule will cease to be subject to Part VII of the Act (section 2). This means that, from the date of operation, which is 1 May 1997, the listed drugs and preparations will no longer be covered under the provisions that relate to the Pharmaceutical Benefits Scheme. The Schedule specifically mentions Ethinyloestradiol, indicating that this substance is the one affected by this legislative change. In terms of obligations and requirements, the Declaration requires that the Assistant Secretary, Pharmaceutical Benefits Branch, Department of Health and Family Services, act as the delegate of the Minister for Health and Family Services. This role involves obtaining advice from the Pharmaceutical Benefits Advisory Committee, as mandated by subsection 85 (2AB) of the Act. The Declaration itself is made pursuant to subsection 85 (2AA), ensuring that the changes to the Pharmaceutical Benefits Scheme are both lawful and informed by expert advice. The Declaration does not explicitly state any offences, penalties, or consequences for breach. However, any non-compliance with the provisions of the National Health Act 1953, including the changes specified in this Declaration, could potentially lead to legal actions under the broader legislative framework. Given the context of the National Health Act, breaches could result in civil or criminal penalties as provided by other sections of the Act, although these are not detailed in the Declaration itself. Overall, this Declaration serves to formally update the Pharmaceutical Benefits Scheme by removing certain drugs and preparations from its coverage, effective from the specified date. The process ensures that the changes are both procedurally sound and based on informed advice, aligning with the legislative intent to maintain a regulated and effective health system in Australia.